United Therapeutics (NASDAQ:UTHR) Downgraded by TheStreet

TheStreet lowered shares of United Therapeutics (NASDAQ:UTHR) from a b rating to a c rating in a research report released on Wednesday, TheStreetRatingsTable reports.

Several other research firms have also recently commented on UTHR. ValuEngine cut United Therapeutics from a sell rating to a strong sell rating in a research note on Thursday, July 2nd. Cowen restated a buy rating and set a $145.00 price target on shares of United Therapeutics in a research note on Friday, June 12th. Wedbush restated a buy rating and set a $244.00 price target (up previously from $243.00) on shares of United Therapeutics in a research note on Wednesday. Zacks Investment Research raised United Therapeutics from a hold rating to a buy rating and set a $128.00 price objective on the stock in a report on Sunday, May 3rd. Finally, Credit Suisse Group upped their price objective on United Therapeutics from $129.00 to $145.00 and gave the stock an outperform rating in a report on Thursday, June 25th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus price target of $141.67.

Shares of NASDAQ UTHR opened at $111.47 on Wednesday. The company has a current ratio of 7.43, a quick ratio of 8.46 and a debt-to-equity ratio of 0.26. United Therapeutics has a twelve month low of $75.58 and a twelve month high of $127.79. The stock has a 50 day moving average of $117.48 and a two-hundred day moving average of $106.45. The stock has a market cap of $5.00 billion, a P/E ratio of 11.65 and a beta of 0.86.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $2.41 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $2.41. United Therapeutics had a return on equity of 14.90% and a net margin of 30.04%. The business had revenue of $362.00 million during the quarter, compared to analysts’ expectations of $339.97 million. During the same quarter in the prior year, the business earned $3.63 earnings per share. The company’s quarterly revenue was down 3.1% compared to the same quarter last year. As a group, research analysts predict that United Therapeutics will post 10.4 earnings per share for the current year.

In other United Therapeutics news, Director Judy D. Olian sold 4,510 shares of the company’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $124.96, for a total value of $563,569.60. Following the sale, the director now owns 3,490 shares of the company’s stock, valued at $436,110.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 10,000 shares of the company’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $115.90, for a total value of $1,159,000.00. Following the completion of the sale, the chief executive officer now directly owns 10,140 shares in the company, valued at approximately $1,175,226. The disclosure for this sale can be found here. Insiders have sold 242,210 shares of company stock worth $28,840,232 in the last ninety days. 10.90% of the stock is currently owned by corporate insiders.

Institutional investors have recently bought and sold shares of the business. Comerica Bank lifted its position in shares of United Therapeutics by 10.4% in the second quarter. Comerica Bank now owns 28,303 shares of the biotechnology company’s stock valued at $3,213,000 after acquiring an additional 2,656 shares in the last quarter. Pzena Investment Management LLC purchased a new stake in shares of United Therapeutics in the second quarter valued at $639,000. UBS Group AG lifted its position in shares of United Therapeutics by 3,445.0% in the second quarter. UBS Group AG now owns 39,420 shares of the biotechnology company’s stock valued at $4,770,000 after acquiring an additional 38,308 shares in the last quarter. Hancock Whitney Corp purchased a new stake in shares of United Therapeutics in the second quarter valued at $422,000. Finally, Signaturefd LLC lifted its position in shares of United Therapeutics by 139.6% in the second quarter. Signaturefd LLC now owns 321 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 187 shares in the last quarter. 97.99% of the stock is currently owned by institutional investors.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Further Reading: Holder of Record

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.